A 61-person Danish trial in type 2 diabetes found six weeks of GIP infusion did nothing for glucose, HbA1c or weight on top of semaglutide.
Recap by typeshit. Full story at Medical Dialogues.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
One writer shares her own unexpected pregnancy while taking the tirzepatide shot, and says many others have been through the same thing.
Loading…